RecruitingACTRN12624000283572

Comparing the effects of high flow nasal oxygen versus face mask oxygen on expired end tidal oxygen concentration after simulated preoxygenation of obese pregnant people

High flow humidified nasal oxygen versus face mask oxygen for preoxygenation of pregnant people with high body mass index – a prospective randomised controlled crossover non-inferiority study (HINOP3)


Sponsor

Dr Patrick CF Tan

Enrollment

100 participants

Start Date

Apr 23, 2024

Study Type

Interventional

Conditions

Summary

This is a randomised controlled trial (highest quality evidence) aimed at comparing a newer technique in oxygen delivery (high flow nasal oxygen) to current industry standard technique (face mask oxygen). The study design simulates conditions immediately before the start of a general anaesthetic to test a crucial safety step called preoxygenation. The specific population we are studying are obese, pregnant people who are in late pregnancy (more than 36 weeks). This group is at a high risk of oxygen problems after the start of a general anaesthetic which makes preoxygenation additionally important. Our hypothesis is that high flow nasal oxygen is not worse than face mask oxygen for preoxygenation in this patient group. The results will inform anaesthetic practice for this high risk patient group.


Eligibility

Sex: FemalesMin Age: 18 YearssMax Age: 50 Yearss

Plain Language Summary

Simplified for easier understanding

When someone needs a general anaesthetic, an important safety step beforehand is 'preoxygenation' — breathing high-concentration oxygen to build up a reserve, giving anaesthetists a safer window if breathing becomes difficult at the start of anaesthesia. This is especially important for pregnant people with obesity, who are at higher risk of oxygen problems. The standard method uses a tight-fitting face mask, but a newer approach called high flow nasal oxygen (HFNO) delivers warm, humidified oxygen through soft prongs in the nostrils, which some patients find more comfortable. This study compares both methods in pregnant women over 36 weeks' gestation with a BMI of 30 or above, to see if HFNO works just as well as the face mask. You may be eligible if you are pregnant at 36 weeks or more, have a BMI of 30 or higher, and have an uncomplicated pregnancy. People with significant nasal problems, severe systemic disease (other than obesity), preeclampsia, active labour, or multiple pregnancy are not eligible. The results of this study will help improve the safety of anaesthetic care for one of the most medically complex groups of patients.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

The intervention will be preoxygenation with high flow humidified nasal oxygen for a total duration of 3 minutes according to the protocol as follows. The approximate total duration of the testing wil

The intervention will be preoxygenation with high flow humidified nasal oxygen for a total duration of 3 minutes according to the protocol as follows. The approximate total duration of the testing will take 30 minutes. High flow humidified nasal oxygen protocol With 10 l.min-1 of room air (FiO2 21%) running in the anaesthetic circuit, a tightly fitting face mask will be applied by a trained investigator (anaesthetist, anaesthetic registrar, medical student, or nurse) and a good seal and ideal fitting will be determined by observing the capnography trace as the woman breathes. (This step may be omitted if the participant undergoes the face mask oxygen protocol first as per randomization). The face mask will then be removed. The oxygen concentration in the anaesthetic circuit will be increased to 100% (FiO2 100%) with flows remaining at 10 l.min-1 until the oxygen concentration rises to 100% as determined by real time oxygen analysis on the anaesthetic machine. After this has been achieved, high flow humidified nasal cannulae (Optiflow Switch™ by Fisher & Paykel Healthcare - TGA approved) will be placed into the woman’s nostrils by the trained investigator (anaesthetist, anaesthetic registrar, medical student, or nurse). The oxygen flow will be commenced (first 30 seconds at 30 l.min-1, then next 150 seconds at 70 l.min-1). Each woman will be instructed to breathe normally with her mouth closed as much as possible. The percentage of time mouth closure is achieved will be recorded to the closest percentage of 0%, 25%, 50%, 75% or 100%. If the maximum (70 l.min-1) flow rate is not tolerated, it will be reduced to 60 l.min-1 and then to 50 l.min-1 before aborting the protocol. At the end of three minutes the participant will be asked to hold their breath in inspiration while the tightly fitting face mask (connected to 10 l.min-1 FiO2 100%) will be applied over the nasal cannulae occluding the compressible arm. The woman will then be asked to exhale normally and breathe normally and the first four etO2 concentration values measured by the end tidal gas analyzer on the anaesthetic machine will be recorded. Other variables including end-tidal carbon dioxide concentration, peak oxygen saturation values and tidal volumes will be recorded.


Locations(1)

The Royal Women's Hospital - Parkville

VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12624000283572


Related Trials